✦ LIBER ✦

Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma

✍ Scribed by Mahalingam, Devalingam; Malik, Laeeq; Beeram, Muralidhar; Rodon, Jordi; Sankhala, Kamalesh; Mita, Alain; Benjamin, Daniel; Ketchum, Norma; Michalek, Joel; Tolcher, Anthony; Wright, John; Sarantopoulos, John

Book ID: 125344316
Publisher: Springer
Year: 2014
Tongue: English
Weight: 262 KB
Volume: 74
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-014-2479-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

413 Phase II study evaluating the effica

413 Phase II study evaluating the efficacy, safety and pharmacodynamic correlative study of dual anti-angiogenic inhibition using Bevacizumab (B) in combination with Sorafenib (S) in patients (pts) with advanced malignant melanoma

✍ D. Mahalingam; M. Beeram; J. Rodon; K. Sankhala; A. Mita; D. Benjamin; J. Michal 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 48 KB

23LBA BEAM: A randomized phase II study

23LBA BEAM: A randomized phase II study evaluating the activity of BEvacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated Advanced Melanoma

✍ S.J. O'Day; K.B. Kim; J.A. Sosman; A.C. Peterson; S. Feng; D.R. Minor; J.P. Frue 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 46 KB

AOSOP3 Combination of bevacizumab and er

AOSOP3 Combination of bevacizumab and erlotinib in the treatment of patients with advanced hepatocellular carcinoma with sorafenib-refractory disease: Results of a pilot phase II study

✍ T. Yau; H. Wong; P. Chan; T.J. Yao; T.T. Cheung; S.T. Fan; R.T. Poon 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 151 KB

Phase I study on the safety, pharmacokin

Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma

✍ Ikeda, Masafumi; Shiina, Shuichiro; Nakachi, Kohei; Mitsunaga, Shuichi; Shimizu, 📂 Article 📅 2014 🏛 Springer US 🌐 English ⚖ 403 KB

A phase I/II, non-randomized, feasibilit

A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer

✍ Sil Kordes, Dick J. Richel, Heinz-Josef Klümpen, Mariëtte J. Weterman, Arnoldus 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 181 KB

A two-part Phase II study of cediranib i

A two-part Phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics

✍ Claire L. Mitchell; J. P. B. O’Connor; C. Roberts; Y. Watson; A. Jackson; S. Che 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 631 KB